drugset / Trial / NCT02524197
A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee
RandomizedParallel-groupSingle-blindTreatment
Summary
To assess the safety and tolerability of orally-administered CR845 in patients with osteoarthritis (OA) of the hip or knee. The study drug is being tested to reduce OA pain, and will be taken twice a day for two weeks, with four different doses (strengths) being tested. From screening period to follow up examination, the study is expected to last for up to 38 days per participant.
Timeline
- Start
- 2015-08
- Primary completion
- 2016-01
- Completion
- 2016-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Difelikefalin | Protein / enzyme biologic | 0.25 mg | Oral |
| Comparator | Difelikefalin | Protein / enzyme biologic | 0.5 mg | Oral |
| Comparator | Difelikefalin | Protein / enzyme biologic | 1 mg | Oral |
| Comparator | Difelikefalin | Protein / enzyme biologic | 5 mg | Oral |